Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
Multiple myeloma (MM) is a neoplastic plasma cell disorder characterized by the expansion and accumulation of clonal plasma cells. The introduction of novel drugs and new therapeutic options has led to significantly higher complete response rates and prolonged progression-free and overall survival (...
| Autores: | , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2023 |
| País: | España |
| Institución: | Consejo Superior de Investigaciones Científicas (CSIC) |
| Repositorio: | DIGITAL.CSIC. Repositorio Institucional del CSIC |
| OAI Identifier: | oai:digital.csic.es:10261/337522 |
| Acceso en línea: | http://hdl.handle.net/10261/337522 |
| Access Level: | acceso abierto |
| Palabra clave: | Minimal residual disease Multiple myeloma Prognostic factor Disease monitoring Flow cytometry |
| Sumario: | Multiple myeloma (MM) is a neoplastic plasma cell disorder characterized by the expansion and accumulation of clonal plasma cells. The introduction of novel drugs and new therapeutic options has led to significantly higher complete response rates and prolonged progression-free and overall survival (1). Despite these advances, MM remains an incurable disease. Thus, there is a need to refine response criteria and methods for more sensitive identification of persistence of lower levels of minimal (measurable) residual disease (MRD) (2). The International Myeloma Working Group has defined the response criteria for patients with MM by including MRD (3). Moreover, depth response based on MRD has emerged as one of the most important independent prognostic factors in MM and has been tested as a dynamic tool for treatment/disease monitoring, prognostication, and as a new (potential) therapeutic endpoint in clinical trials and drug approval for MM patients (4). |
|---|